In late May 2023, clinical-stage biotechnology company AiViva Biopharma Inc. ("AiViva") shared via news release that the company had launched a Phase 1 clinical study evaluating AIV007 for diabetic…
An announcement from the drug company Genentech highlights the results of a recent study which demonstrated that the drug faricimab-svoa (marketed at Vabysmo) was able to dry retinal fluid more…
In a late April 2023 news release, biotechnology company UNITY Biotechnology, Inc. ("UNITY") shared that the company had observed positive long-term follow-up data from the Phase 2 BEHOLD trial. Within…
According to a story from Market Screener, the biotech company UNITY Biotechnology, Inc., has recently announced the release of data from 12 weeks and 18 weeks of its Phase 2…
On February 7, 2022, Healthline reported that the FDA had approved Vabysmo (faricimab-svoa), an injectable therapy for those with wet age-relate macular degeneration (wAMD) and diabetic macular edema. This approval…
The FDA has recently accepted Genentech's Biologics License Application (BLA) under priority review. This application was for faricimab, a bispecific antibody meant to treat ocular disorders, such as wet age-related…
In a recent news release, pharmaceutical company Tarsier Pharma ("Tarsier") shared that it held a successful pre-Investigational New Drug (pre-IND) meeting with the FDA. The meeting focused on TRS02, a…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
